Waud Capital Partners

Industry:	Healthcare Services – Specialty pharmaceuticals
Headquarters:	Palo Alto, California
Date of Investment:	April 2004
Fund:	WCP Fund I
Date of Exit:	November 2010
Website:	jazzpharmaceuticals.com
Add-on Acquisition Orphan Medical – June 2005
Related News 06/10 Jazz Pharmaceuticals Announces Additions to Board of Directors 05/10 Jazz Pharmaceuticals Announces Pricing of Public Offering of Common Stock 12/09 Jazz Pharmaceuticals Submits New Drug Application 06/07 Jazz Pharmaceuticals Announces Initial Public Offering 02/07 Jazz and Solvay Pharmaceuticals Announce License Agreement For LUVOX 01/07 Jazz Signs Licensing Agreement With Valeant Pharmaceuticals 09/06 Phase III Clinical Trial to Study the Safety and Efficacy of Xyrem® 06/05 Jazz Pharmaceuticals Completes Acquisition of Orphan Medical 04/05 Jazz Pharmaceuticals to Acquire Orphan Medical 04/04 WCP Completes Investment in Jazz Pharmaceuticals

“Waud Capital was an important group within our distinguished team of investors. The firm’s network of contacts and experience investing
in the healthcare industry
brought value to us as we built our business. ”

Dr. Sam Saks
Former Chief Executive Officer